Article Text

other Versions

PDF
Is surveillance of the small bowel indicated for Lynch syndrome families?
  1. Gerrit Luit ten Kate (gltenkate{at}gmail.com)
  1. Dutch HNPCC Registry Leiden & Department of Gastroenterology of the Leiden University Medical Centre, Netherlands
    1. Jan H Kleibeuker
    1. Department of Gastroenterology University Medical Centre Groningen, Netherlands
      1. Fokko M Nagengast
      1. Department of Gastroenterology University Medical Centre Nijmegen, Netherlands
        1. Mike Craanen
        1. Department of Gastroenterology Free University Medical Centre Amsterdam, Netherlands
          1. Annemieke Cats
          1. National Cancer Institute Amsterdam, Netherlands
            1. Fred H Menko
            1. Department of Clinical Genetics Free University Medical Centre Amsterdam, Netherlands
              1. Hans FA Vasen (hfavasen{at}stoet.nl)
              1. Dutch HNPCC Registry Leiden & Department of Gastroenterology of the Leiden University Medical Centre, Netherlands

                Abstract

                Introduction: Small bowel cancer (SBC) is one of the tumors associated with Lynch Syndrome (LS). To advise on screening for this tumor it is paramount to be informed about the lifetime risk. The aim of the present study was to calculate the lifetime risk of SBC in LS and to identify possible risk factors.

                Patients and methods: Clinical and pathological data were collected on 1496 proven or putative carriers of a mismatch repair-gene mutation from 189 families. Kaplan-Meier survival analysis was used to calculate the lifetime risk and to assess potential risk factors. Results: 28 (1.9%) of the 1496 (putative) mutation carriers were identified with SBC. The median age at diagnosis was 52 years (range: 23-69 years). The lifetime risk of developing SBC was 4.2%. There was no difference in risk between males and females (log rank: p=0.2470), nor between MLH1 and MSH2 mutation carriers (log rank: p=0.2754). SBC was not observed in MSH6 mutation carriers (n=203). The previous occurrence of colorectal cancer and a family history of SBC did not increase the risk significantly.

                Conclusions: Approximately, one out of 25 mutation carriers will develop SBC during life. No specific risk factors were identified. The risk appeared to be too low to advise screening by means of an invasive burdensome procedure like double-balloon enteroscopy. However, screening by a non-invasive procedure (videocapsule-endoscopy) might be considered if future studies will show its cost-effectiveness. In patients with unexplained abdominal complaints and/or unexplained iron-deficiency anemia SBC should be considered.

                • hereditary nonpolyposis colorectal cancer
                • lynch syndrome
                • small bowel cancer

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                Linked Articles

                • Digest
                  Robin Spiller Emad El-Omar